HEMNOS clinical trials at UCSF
1 research study open to eligible people
Hemnos is a group of clinical trials for cancers that start in the liver. UCSF is testing engineered immune cells and other therapies for safety. UCSF is studying these treatments in children with liver tumors.
Showing trials for
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
open to eligible people ages 1-21
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
San Francisco, California and other locations
Our lead scientists for HEMNOS research studies include Arun Rangaswami.
Last updated: